FDA approves Sanofi drug delivered with Enable on-body device

FDA approved Sanofi's Sarclisa anticancer therapy delivered via Enable Injections' on-body wearable device (CirCLIQ), marking the first FDA-cleared on-body injector for cancer treatment. The approval follows Sanofi's $30m investment in Enable and enables subcutaneous administration as an alternative to intravenous infusion for multiple myeloma patients. You're building wearable drug delivery or oncology infrastructure: Sanofi just proved there's a large-volume cancer treatment market willing to move from IV chairs to at-home subcutaneous injection, and Enable is now the reference design that pharma companies will chase. The commercial play is not the device—it's becoming the delivery partner every oncology company needs to upgrade their franchise.